Gum Disease, H. Pylori, and Emerging Risk Factors
Beyond the well-established factors, a cluster of emerging associations deserves mention, particularly for readers who consider themselves otherwise low-risk.
Periodontal (gum) disease and tooth loss appear to be linked to pancreatic cancer, even when controlling for other risk factors. While the biological mechanism is not fully understood, chronic bacterial inflammation in the mouth may influence systemic inflammatory pathways that affect pancreatic tissue.
Some research suggests that infection of the stomach with the ulcer-causing bacteria Helicobacter pylori (H. pylori) or infection with hepatitis B may increase the risk of getting pancreatic cancer, though more studies are needed.
Research also suggests that exposure to certain environmental chemicals and heavy metals may increase the risk of developing pancreatic cancer. This includes occupational exposure to pesticides and solvents, a risk factor that receives far less public attention than smoking or diet but has been documented in agricultural and industrial worker populations.
These associations remain areas of active investigation rather than confirmed causal relationships. Their presence in the risk profile, however, reinforces the importance of treating chronic infections and maintaining oral health as part of overall cancer prevention.
When Risk Factors Combine
One of the most important findings from recent research is what happens when risk factors appear together. They do not simply add up. In some combinations, they multiply.
The 2025 Yonsei study showed that patients with both type 2 diabetes and pancreatitis faced roughly five times the cancer risk of those with neither condition. In post-pancreatitis diabetes patients on insulin, the risk was more than 17-fold higher. An older but frequently cited UK cohort study published in PubMed found that patients with type 2 diabetes and chronic pancreatitis were 12 times more likely to develop pancreatic cancer.
Smoking combined with diabetes, or obesity combined with a BRCA2 mutation, creates cumulative risk profiles that are not routinely assessed in standard primary care. This is partly why early detection remains so poor.
Early screening for pancreatic cancer should be considered in populations at high risk, including individuals with multiple close family members affected by the disease, those with a pathogenic variant in a high-risk gene, or people with a history of pancreatic cysts. If you carry two or more of the risk factors described in this report, raising the question of surveillance with your doctor is a reasonable step.
